Composing report
01 / 06
Download PDF
InvestHouse Research
Research subjectNeurizon Therapeutics LtdNUZ:ASX
Report cycleQ3 FY26 UPDATEAs at 05 Nov 2026
Report01/ 06

Funding the next gate without overpaying

Neurizon Therapeutics is a clinical-stage biotechnology company, with pipeline and regulatory proof points setting the investment case; ASX - FY2026 Research Report operates at the centre of this investment case; valuation depends on execution proof points.

Investment conclusion

HEALEY enrolment complete, topline now due in late Q2 CY27

Neurizon is a pre-revenue, single-asset biotech with NUZ-001 in ALS at the centre of the case. We rate it Hold. The stock matters because the lead program has moved from permission and setup into an active late-stage readout path, with the FDA hold lifted, first dosing completed in February 2026 and enrolment now complete at 250 participants in Regimen I of the HEALEY ALS Platform Trial.

Market vs house disagreement

The market is still discounting the readout, not the asset

The market value is about A$53.7m at A$0.11 a share, while the recent strategic package has improved the operating runway and the HEALEY enrolment update has removed a major execution overhang. We think the market is still treating NUZ-001 as a binary clinical story, when the more important change is that the company has now delivered three dated steps, FDA clearance, first patient dosing and full enrolment, against a 36-week treatment and 36-week extension design.

Catalysts

What the target depends on

  • The current share price is 11.0c, and the stock still trades on late-stage clinical risk rather than current earnings, because the company has no commercial revenue and the key value gate is the Q2 CY2027 readout.
  • The house target is not available, so the valuation call remains anchored to whether the market gives NUZ-A$0.201 credit for HEALEY execution, the Elanco supply agreement executed on 17 June 2026, and the 2041 patent life.
  • The main discount is timing and funding risk, but the clinical pathway is now more visible after 250 participants were enrolled in under five months, and the liquid formulation study due to start in Q3 2026 adds a nearer catalyst.
Funding / thesis break

What would change the call

  • Topline data in late Q2 CY2027 would be the first clean test of whether NUZ-001 can carry a disease-modifying ALS thesis into the next valuation step.
  • Failure to keep the HEALEY and formulation timelines moving would pull the stock back to financing and delay risk, especially if any further slip pushes the readout beyond late Q2 CY2027.
  • Additional supply or regulatory friction would matter less now that the five-year Elanco agreement is executed, but any quality or continuity issue in GMP monepantel would still slow commercial readiness.
Verified and compiled byIvan Tchourilov23 July 2026

General information only: This report is general in nature and has been prepared without taking into account your objectives, financial situation or needs. Consider whether it is appropriate for you and seek licensed advice where required.

This report has not been commissioned or paid for by the company and may be AI-assisted. See Important Disclosures for publisher, conflicts, research policy and distribution information.

© 2026 InvestHouse Financial Services Pty Ltd. All rights reserved.

Cover · Investment SummaryInvestHouse
Neurizon Therapeutics LtdResearch ReportInvestHouse Research
NUZ : ASXPAGE 02 / 06
Quarterly evidence
02

Recruitment is complete

The 250-patient cohort is now in treatment. Recruitment is in place. the programme still has to show a clinical effect.

Quarterly snapshot
Cash and quarterly burn
CASH A$12.7M · BURN A$6.4M/QTRQ1Q2Q3Q4Q5Q6Q7Q8FUNDED · 4.3 QTRS INCL. FACILITIESQUARTERS OF RUNWAY AT LATEST BURNR&D / CLINICAL SPEND A$0.0M · ADMIN A$0.8M
Sep 25Open
Dec 25Open
Mar 26Open
Jun 26Open
Cash
A$6.57m
A$7.94m
A$16.7m
A$12.7m
Receipts
—
A$0.00m
A$0.00m
A$0.00m
Burn
A$3.83m
A$4.75m
A$0.46m
A$6.37m
Investor read-through
Execution advanced; clinical proof remains the value gate
DeliveredRecruitment and supplyChanges execution risk
Not answeredEfficacy and safetyRequires controlled clinical evidence
FundingModelled separatelyFinancial page owns funding treatment

Quarterly milestones can improve the path to data without changing the standard of proof required for value realisation.

What completing recruitment changes

Recruitment is complete at 250 patients. Supply is contracted. That improves readiness for the readout without speaking to its result.

What the filing has de-risked

The filing confirms recruitment completion and supply readiness. This is execution evidence: it improves readiness, timing or supply confidence, rather than providing a clinical efficacy result.

What still has to be proven

The readout still needs to establish effect size, statistical reliability, missing-data handling and safety. The investment case therefore remains conditional on the next decision-grade clinical catalyst, not on this operating update alone.

Recruitment complete · Quarterly evidenceInvestHouse
Neurizon Therapeutics LtdResearch ReportInvestHouse Research
NUZ : ASXPAGE 03 / 06
Clinical underwriting
03

Project economics and execution path

What is already de-risked

QuestionAnswer
Can it work?Yes, the lead asset has already cleared FDA clinical hold, entered the HEALEY ALS Platform Trial, and enrolled 250 participants in under five months as at 17 July 2026.
House convictionModerate. The trial architecture and execution speed support the asset, but it remains a single-asset story until blinded efficacy data arrive in late Q2 CY2027.
Strongest evidence129 of 240 participants had been dosed by 9 June 2026, more than 50% ahead of schedule, and enrolment later completed at 250 participants.
Biggest uncertaintyRandomised efficacy and safety readout from the 36-week treatment period, then the 36-week active-treatment extension.
Missing proofControlled data showing NUZ-001 can reproduce or improve on the earlier historical-control signals.
What would change the answerA positive topline result in late Q2 CY2027, with tolerability intact and a clean path into the next regulatory step.

NUZ-001 is the whole asset base. It is an oral small molecule in ALS, a disease where swallowing difficulty becomes material, so the planned oral liquid study matters commercially as well as clinically. Bellberry ethics approval was received on 13 May 2026 for a 32-volunteer Phase 1 formulation study in Australia, which is due to start in Q3 CY2026 and finish in Q4 CY2026. That keeps the product work aligned with the HEALEY ALS platform program, rather than sitting as an isolated side project.

What is already real: the company has both manufacturing and trial infrastructure in place. A five-year supply agreement with Elanco was executed on 17 June 2026 for human-grade GMP monepantel, and three GMP tablet registration batches have already been completed by Catalent. Together with the expanded 240-participant HEALEY regimen, that reduces the chance that the program is held back by supply chain immaturity rather than science.

What still has to work

FactorRead-throughEvidence
Product qualityMixed to goodPhase 1 and open-label extension data were supportive, but they were not randomised registrational data.
Technical proofGood, but not completeEnrolment completed and dosing has progressed through the 36-week randomised treatment period.
Manufacturing readinessGoodFive-year Elanco supply, quality agreement, and completed GMP registration batches.
JurisdictionGoodCore development is in the US and Australia, with FDA entry already secured.
Management executionBetter than the market may be giving credit forRegimen expansion from 160 to 240 participants and accelerated topline timing came after recruitment outpaced the original plan.

What that means: the stock is no longer being asked to underwrite a theoretical asset. It is being asked to underwrite a late-stage ALS dataset that is already in motion, with formulation work and API supply now positioned around the same lead program. The key valuation swing factor is not whether the company has a program, but whether the Q2 CY2027 readout confirms the earlier signal cleanly enough to justify the next capital step and any partnering interest.

Bottom line
Mechanism and open-label signals justify underwriting the trial; only controlled efficacy can validate the disease-modifying case.
Project economics and execution path · Clinical underwritingInvestHouse
Neurizon Therapeutics LtdResearch ReportInvestHouse Research
NUZ : ASXPAGE 04 / 06
i.
Financial Lens

Clinical rNPV, Funding & Dilution

How clinical probability, regional peak-sales assumptions, development cost, net cash and expected dilution convert into per-share value.

Latest Quarterly Metrics
Cash
A$12.7m
30 June 2026
Quarterly Burn
A$6.37m
latest structured quarter
Runway
4.3 qtrs
before modelled financing
Target
A$0.201
risk-adjusted, diluted
Mkt CapA$49.1MSpotA$0.062
Financial Lens

Financial summary

NUZ.ASX: focus on liquidity, capex/funding gap, and timeline to cash flow — not headline EPS. > Can the company fund the next value gate on acceptable terms? Lens conclusion: current data may cover near-term study and execution work, but the path to first cash flow is not yet proven to be self-funded. ### Funding & execution
  • How much cash is left?
  • How much more is needed?
  • Can they bridge to cash flow without heavy dilution? ## Runway vs milestones
  • FY2023: revenue 0.0m, EBITDA n/am, NPAT -6.2m, net debt -1.7m
  • FY2024: revenue 0.0m, EBITDA n/am, NPAT -7.7m, net debt -9.7m
  • FY2025: revenue 0.0m, EBITDA n/am, NPAT -16.6m, net debt -4.2m
  • Forward estimate rows unavailable. ## Funding risk to equity
  • Map cash runway to the next funding or study milestone.
  • Stress-test dilution if equity is required before operating cash flow.
  • Watch mismatch between study/restart timing and financing windows.
  • Current cash likely covers near-term work, but not the full path to cash flow without additional funding.
Bottom line — show the metrics that govern how this stock type is underwritten — not every field Refinitiv happens to publish.
Financial analysisInvestHouse
Neurizon Therapeutics LtdResearch ReportInvestHouse Research
NUZ : ASXPAGE 05 / 06
05

Leadership & Register

Registeras at 22 Aug 2025Boardas at 03 Aug 2026Peers1 comps
Execution scorecardDelivery against the milestones that de-risk the next value gate
delivered
Clinical access

The stock matters because the lead program has moved from permission and setup into an active late-stage readout path, with the FDA hold lifted, first dosing completed in February 2026 and enrolment now complete at 250 participants in Regimen I of the HEALEY ALS Platform Trial.

delivered
Recruitment

HEALEY enrolment complete, topline now due in late Q2 CY27 Neurizon is a pre-revenue, single-asset biotech with NUZ-001 in ALS at the centre of the case.

delivered
CMC & supply

- The house target is not available, so the valuation call remains anchored to whether the market gives NUZ-A$0.201 credit for HEALEY execution, the Elanco supply agreement executed on 17 June 2026, and the 2041 patent life.

watch
Funding path

The model shows no near-term raise; reconcile trial budget, latest reported cash and runway before treating funding as secured.

delivered
Commercial rights

Persisted territory and partner economics support the retained-value case.

Board & Key PersonnelComposition
01
Sergio DuchiniChair
Interim Executive Chairman with board and executive experience spanning professional services, life sciences, biotechnology, banking and finance.
02
Kathryn (Katie) MacfarlaneNon-Executive Director
Non-Executive Director with more than 30 years of pharmaceutical product development and commercialisation experience.
03
Marcus HughesNon-Executive Director
Non-Executive Director with more than 20 years of listed-company experience and expertise in corporate finance, project financing and capital raisings.
04
Ross Thomas MurdochNon-Executive Director
Independent Non-Executive Director with more than 30 years of pharmaceutical, biotechnology and healthcare experience, including neurology and neurodegenerative disease programs.
Top 20 ShareholdersOrdinary shares • NUZ
as at 22 Aug 2025 · latest disclosed register available · board 03 Aug 2026
Bottom line
Board capability supports execution, but territory ownership, royalty obligations and retained economics remain a publication diligence item.
Leadership & RegisterInvestHouse
Neurizon Therapeutics LtdResearch ReportInvestHouse Research
NUZ : ASXPAGE 06 / 06
Important Disclosures & Disclaimer

Important disclosures
and disclaimer

General information only. Not personal advice. Readers should assess suitability and seek licensed advice where appropriate.

Publisher and Regulatory Status
This research has been prepared and published by InvestHouse Financial Services Pty Ltd (ACN 669 520 174). InvestHouse Financial Services Pty Ltd is a Corporate Authorised Representative (No. 001304496) of Point Capital Group Pty Ltd (ABN 41 625 931 900), holder of Australian Financial Services Licence No. 518031. The views, opinions, recommendations, valuations, and price targets expressed in this research are those of InvestHouse and the identified author(s).
General Information Only
This document is supplied solely for information. Any financial advice contained in it is general only and has been prepared without reference to any person's objectives, financial situation or needs. Investors should assess the appropriateness of the information in light of their own circumstances and, where appropriate, seek advice from a licensed financial adviser before acting on it.
Nature of the Research
The views expressed in this report reflect the opinions of the author(s) as at the date of publication and are based on publicly available information believed to be reliable at the time of writing. Forecasts, estimates, valuations, price targets, and forward-looking statements are inherently uncertain and subject to change without notice. This report does not constitute an offer or invitation to purchase securities and should not be relied upon in connection with any contract or commitment.
Conflicts of Interest
InvestHouse Financial Services Pty Ltd, its related entities, directors, officers, employees, or associates may have provided, may currently provide, or may in the future provide corporate advisory, capital markets, investor relations, media, consulting, or other commercial services to companies mentioned in this report. They may also trade in securities that are the subject of this report and may earn brokerage, commissions, fees, or other benefits in connection with recommendations or dealings by clients in those securities. Some representatives may be remunerated wholly or partly by commission.
Analyst Certification
Each analyst or author responsible for this report certifies that the final published views, opinions, valuations, and price targets accurately reflect their personal, independent, and objective assessment of the securities or issuers discussed. No part of their compensation was, is, or will be directly or indirectly related to the specific recommendations, opinions, valuations, or price targets expressed in this report.
Research Policy and FSG
InvestHouse Financial Services Pty Ltd maintains internal arrangements designed to manage research independence, conflicts of interest, and separation between research, advisory, corporate, and capital markets activities. For further information, refer to the current Financial Services Guide and Research Independence Policy.
No Warranty or Liability
While this report is based on sources considered reliable, InvestHouse Financial Services Pty Ltd has not independently verified all information contained in this document and does not represent, warrant, or guarantee, expressly or impliedly, that it is complete or accurate. InvestHouse Financial Services Pty Ltd accepts no responsibility to update any advice, views, opinions, or recommendations or to correct any error or omission that becomes apparent after publication.
Jurisdiction and Distribution
This document is not directed to, or intended for distribution to or use by, any person or entity in any locality, state, country, or jurisdiction where distribution, publication, availability, or use would be contrary to law or regulation, or would subject InvestHouse Financial Services Pty Ltd to any registration or licensing requirement. Specific jurisdictional restrictions may apply outside Australia.
Copyright and Use
© 2026 InvestHouse Financial Services Pty Ltd. All rights reserved. All material presented in this document, unless specifically indicated otherwise, is under copyright to InvestHouse Financial Services Pty Ltd. This document is a private communication disseminated by InvestHouse Financial Services Pty Ltd and must not be altered, transmitted, copied, distributed, or used by any other party without its prior written consent.
AI-Assisted Research and Analyst Review
InvestHouse Research uses a combined AI and analyst-review pathway. AI tools may assist with data extraction, summarisation, drafting, modelling support, editing, and report structuring. The final report is reviewed by an analyst or author before publication, but AI-assisted workflows and source data may still contain errors, omissions, or inaccuracies. Readers should independently verify all material information.
By accessing this report, you acknowledge these disclosures · For distribution only where lawful · InvestHouse Research